Kidney dosimetry in [ 177 Lu]Lu-DOTA-TATE therapy based on multiple small VOIs

被引:0
|
作者
Kapidzic, Selma Curkic [1 ,2 ,3 ]
Gustafsson, Johan [1 ]
Larsson, Erik [2 ]
Jessen, Lovisa [1 ]
Gleisner, Katarina Sjogreen
机构
[1] Lund Univ, Med Radiat Phys, Lund, Sweden
[2] Skane Univ Hosp, Dept Hematol Oncol & Radiat Phys, Radiat Phys, Malmo, Sweden
[3] Skanes Univ Sjukhus, Barngatan 4, S-22185 Lund, Sweden
关键词
177; Lu-PRRT; Quantitative SPECT; Dosimetry; Kidneys; RECEPTOR RADIONUCLIDE THERAPY; PATIENT-SPECIFIC DOSIMETRY; IMAGE-BASED DOSIMETRY; NEUROENDOCRINE TUMORS; SPECT; ACCELERATION;
D O I
10.1016/j.ejmp.2024.103335
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: The aim was to investigate the use of multiple small VOIs for kidney dosimetry in [ 177 Lu]Lu-DOTA-TATE therapy. Method: The study was based on patient and simulated SPECT images in anthropomorphic geometries. Images were reconstructed using two reconstruction programs (local LundaDose and commercial Hermia) using OS -EM with and without resolution recovery (RR). Five small VOIs were placed to determine the average activity concentration (AC) in each kidney. The study consisted of three steps: (i) determination of the number of iterations for AC convergence based on simulated images; (ii) determination of recovery -coefficients (RCs) for 2 mL VOIs using a separate set of simulated images; (iii) assessment of operator variability in AC estimates for simulated and patient images. Five operators placed the VOIs, using for guidance: a) SPECT/CT with RR, b) SPECT/CT without RR, and c) CT only. For simulated images, time -integrated ACs (TIACs) were evaluated. For patient images, estimated ACs were compared with results of a previous method based on whole -kidney VOIs. Results: Eight iterations and ten subsets were sufficient for both programs and reconstruction settings. Mean RCs (mean +/- SD) with RR were 1.03 +/- 0.02 (LundaDose) and 1.10 +/- 0.03 (Hermia), and without RR 0.91 +/- 0.03 (LundaDose) and 0.94 +/- 0.03 (Hermia). Most stable and accurate estimates of the AC were obtained using five 2mL VOIs guided by SPECT/CT with RR, applying them to images without RR, and including an explicit RC for recovery correction. Conclusion: The small VOI method based on five 2-mL VOIs was found efficient and sufficiently accurate for kidney dosimetry in [ 177 Lu]Lu-DOTA-TATE therapy.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Concomitant Dosimetry During Radionuclide Peptide Therapy with 177-Lu-DOTA-tate and 177-Lu-Lanreotide
    Heute, D. R.
    Dobrozemsky, G.
    Traub, T.
    Warwitz, B.
    von Guggenberg, E.
    Gabriel, M.
    Virgolini, I.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 : S202 - S202
  • [22] Efficacy of the personalized, dosimetry-based PRRT treatment of patients with neuroendocrine tumors using [177Lu]Lu-DOTA-TATE or [177Lu]/[90Y]Lu/Y-DOTA-TATE mixture - the DUONEN multicenter study
    Opalinska, M.
    Mikolajczak, R.
    Kaminski, G.
    Dedecjus, M.
    Kowalska, A.
    Kolodziej, M.
    Saracyn, M.
    Garnuszek, P.
    Cieszykowska, I.
    Sowa-Staszczak, A.
    Hubalewska-Dydejczyk, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S369 - S369
  • [23] Navigating nephrotoxicity: insights from 4 years of [177Lu]Lu-DOTA-TATE therapy at our institution
    Sousa, E.
    Sousa, R.
    Fraga, D.
    Carvalho, I. P.
    Vitorino, I.
    Rombo, D.
    Aco, J.
    Jorge, P.
    Salgado, L.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S667 - S667
  • [24] Epidemiology of Neuroendocrine Neoplasms and Results of Their Treatment with [177Lu]Lu-DOTA-TATE or [177Lu]Lu-DOTA-TATE and [90Y]Y-DOTA-TATE-A Six-Year Experience in High-Reference Polish Neuroendocrine Neoplasm Center
    Durma, Adam Daniel
    Saracyn, Marek
    Kolodziej, Maciej
    Jozwik-Plebanek, Katarzyna
    Dmochowska, Beata
    Kapusta, Waldemar
    Zmudzki, Wawrzyniec
    Mroz, Adrianna
    Kos-Kudla, Beata
    Kaminski, Grzegorz
    CANCERS, 2023, 15 (22)
  • [25] A nuclear beacon of hope: an advanced, metastatic glucagonoma treated with [177Lu]Lu-DOTA-TATE
    Klosinska, Martyna
    Kolodziej, Joanna
    Mroz, Adrianna
    Madra, Weronika
    Kaminski, Grzegorz
    NUCLEAR MEDICINE REVIEW, 2024, 27 : 39 - 41
  • [26] Enhancing [177Lu]Lu-DOTA-TATE therapeutic efficacy in vitro by combining it with metronomic chemotherapeutics
    Cheng, Jordan
    Zink, Joke
    O'Neill, Edward
    Cornelissen, Bart
    Nonnekens, Julie
    Livieratos, Lefteris
    Terry, Samantha Y. A.
    EJNMMI RESEARCH, 2024, 14 (01):
  • [27] Improved prediction of haematological toxicity during [177Lu]Lu-DOTA-TATE therapy by optimising serial SPECT-CT red marrow dosimetry
    Tipping, J.
    Page, E.
    Calvert, N.
    Hamilton, D.
    Cullen, D.
    Price, E.
    Pells, S.
    Needham, G.
    Manoharan, P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S239 - S239
  • [28] Overcoming nephrotoxicity in peptide receptor radionuclide therapy using [177Lu]Lu-DOTA-TATE for the treatment of neuroendocrine tumours
    Geenen, Lorain
    Nonnekens, Julie
    Konijnenberg, Mark
    Baatout, Sarah
    De Jong, Marion
    Aerts, An
    NUCLEAR MEDICINE AND BIOLOGY, 2021, 102 : 1 - 11
  • [29] Trial in Progress: [177Lu]Lu-DOTA-TATE Combination Therapy in Treatment-Naive Extensive Stage Small Cell Lung Cancer
    Liu, S.
    Planchard, D.
    Herrmann, K.
    D'Amelio, A., Jr.
    Folitar, I.
    Ares, L. Paz
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S534 - S534
  • [30] Relationship between absorbed dose and response in neuroendocrine tumors treated with [177Lu]Lu-DOTA-TATE
    Warfvinge, C. F.
    Gustafsson, J.
    Roth, D.
    Tennvall, J.
    Svensson, J.
    Bernhardt, P.
    Akesson, A.
    Wieslander, E.
    Sundlov, A.
    Gleisner, Sjogreen K.
    JOURNAL OF NEUROENDOCRINOLOGY, 2024, 36 : 221 - 221